Mifeprex (mifepristone) / Danco Laboratories 
Welcome,         Profile    Billing    Logout  
 94 Diseases   58 Trials   58 Trials   2914 News 


«12...27282930313233343536373839»
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Î±-Lipoic Acid Vaginal Administration Contrasts Inflammation and Preterm Delivery in Rats. (Pubmed Central) -  Apr 19, 2019   
    The treatment did not affect the implantation process and was able to significantly revert mifepristone plus prostaglandin E2 effects, delaying the timing of delivery and significantly decreasing mRNA synthesis and release of pro-inflammatory cytokines. We provide for the first time new information on vaginal ALA use, even during pregnancy, opening a perspective for further studies.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  Medication Abortion Via Pharmacy Dispensing (clinicaltrials.gov) -  Apr 17, 2019   
    P4,  N=250, Recruiting, 
    This study thus presents an unexpected molecular mechanism by which GRβ could repress transcription. Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    New P4 trial:  Mail Order Mifepristone Study (clinicaltrials.gov) -  Apr 11, 2019   
    P4,  N=425, Not yet recruiting, 
  • ||||||||||  Esmya (ulipristal acetate) / ASKA, HRA Pharma, Allergan, Gedeon Richter, Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  Interventions for emergency contraception. (Pubmed Central) -  Apr 11, 2019   
    Menstrual delay was probably the main adverse effect of mifepristone and seemed to be dose-related. Cu-IUD may be associated with higher risks of abdominal pain than ECPs.
  • ||||||||||  Esmya (ulipristal acetate) / ASKA, HRA Pharma, Allergan, Gedeon Richter, vilaprisan (BAY 1002670) / Bayer, Mifeprex (mifepristone) / Danco Laboratories
    Journal:  UPA effects on endometrium - what is the significance? (Pubmed Central) -  Apr 9, 2019   
    EPAEC was associated with abundant Ki67 antigen. UPA administration for three months is a safe method without endometrial atypia but longer protocols require extended studies about the proliferative potential of the endometrium.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Electroacupuncture of Hegu(LI 4) and Sanyinjiao(SP 6) Assists Medicinal Abortion (Pubmed Central) -  Apr 7, 2019   
    These findings demonstrate the immunomodulatory and immunosuppressant effects of LASSBio-1386 and indicate this molecule is a promising pharmacologic agent for immune-mediated diseases. EA stimulation of Hegu(LI 4) and Sanyinjiao(SP 6) has a positive effect in assisting medicinal abortion in reducing abdominal pain and shortening foetal sac discharge duration.
  • ||||||||||  Esmya (ulipristal acetate) / ASKA Pharma, HRA Pharma, Gedeon Richter, AbbVie, Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial initiation date, Trial primary completion date:  Advance Provision of Medication Abortion (clinicaltrials.gov) -  Apr 4, 2019   
    P4,  N=50, Not yet recruiting, 
    The latter could be exploited for future drug design and to overcome pharmacoresistance. Trial completion date: Apr 2020 --> Jan 2021 | Initiation date: May 2019 --> Jan 2020 | Trial primary completion date: Apr 2020 --> Jan 2021
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Clinical, Review, Journal:  Medical and surgical abortion for women living with HIV. (Pubmed Central) -  Mar 28, 2019   
    We found no evidence suggesting that medical or surgical abortions are unsafe for women living with HIV. While additional research would strengthen the evidence base, healthcare providers should not be deterred from providing access to safe abortion to their patients living with HIV.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial initiation date:  Cervical Preparation With Mifepristone Prior to Osmotic Dilators (clinicaltrials.gov) -  Mar 21, 2019   
    P2,  N=66, Recruiting, 
    The results confirm the topical popular use ofT.catharinensis leaves in the treatment of skin inflammation and demonstrate the TcE' potential for the development of a promising topical anti-inflammatory agent to treat inflammatory disorders. Initiation date: Dec 2018 --> Apr 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date, BRCA Biomarker, IO biomarker:  BRCA1/2 and Effect of Mifepristone on the Breast (clinicaltrials.gov) -  Feb 28, 2019   
    P2,  N=45, Recruiting, 
    Trial completion date: Dec 2018 --> Mar 2020 | Trial primary completion date: Jul 2018 --> Oct 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial termination, Trial primary completion date:  Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=22, Terminated, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2017 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2016; Funding ended
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Enrollment open:  Blocking Mifepristone Action With Progesterone (clinicaltrials.gov) -  Feb 21, 2019   
    P1/2,  N=40, Recruiting, 
    Trial completion date: Dec 2017 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2016; Funding ended Not yet recruiting --> Recruiting
  • ||||||||||  Esmya (ulipristal acetate) / ASKA Pharma, HRA Pharma, Gedeon Richter, AbbVie, Mifeprex (mifepristone) / Danco Laboratories
    New P4 trial:  Advance Provision of Medication Abortion (clinicaltrials.gov) -  Feb 4, 2019   
    P4,  N=50, Not yet recruiting, 
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    New P2 trial, BRCA Biomarker, IO biomarker:  BRCA1/2 and Effect of Mifepristone on the Breast (clinicaltrials.gov) -  Jan 19, 2019   
    P2,  N=45, Not yet recruiting, 
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Enrollment open:  Cervical Preparation With Mifepristone Prior to Osmotic Dilators (clinicaltrials.gov) -  Jan 16, 2019   
    P2,  N=66, Recruiting, 
    Active, not recruiting --> Terminated; Lack of funding Not yet recruiting --> Recruiting
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    New P1/2 trial:  Blocking Mifepristone Action With Progesterone (clinicaltrials.gov) -  Dec 12, 2018   
    P1/2,  N=40, Not yet recruiting, 
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date, Metastases:  Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (clinicaltrials.gov) -  Dec 10, 2018   
    P1/2,  N=108, Recruiting, 
    Active, not recruiting --> Terminated; lack of funding Trial completion date: Aug 2018 --> Dec 2021 | Trial primary completion date: Jul 2018 --> Dec 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Enrollment closed, Trial completion date, Trial primary completion date:  Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial (clinicaltrials.gov) -  Nov 21, 2018   
    P4,  N=416, Active, not recruiting, 
    Trial completion date: Aug 2018 --> Dec 2021 | Trial primary completion date: Jul 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Jan 2017 --> Dec 2018 | Trial primary completion date: Jan 2017 --> Dec 2018
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Enrollment closed, Trial completion date, Trial primary completion date:  Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death (clinicaltrials.gov) -  Nov 21, 2018   
    P3,  N=200, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jan 2017 --> Dec 2018 | Trial primary completion date: Jan 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2017 --> Dec 2018 | Trial primary completion date: Jun 2017 --> Dec 2018
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion, Enrollment change, Trial completion date, Metastases:  Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Sep 12, 2018   
    P1,  N=9, Completed, 
    The results from this study involving a limited number of clinical samples should pave the way for a larger study to determine the safety of UPA for long-term use. Active, not recruiting --> Completed | N=32 --> 9 | Trial completion date: Nov 2018 --> May 2018
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso (clinicaltrials.gov) -  Aug 8, 2018   
    P3,  N=100, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Enrollment open:  Medication Abortion Via Pharmacy Dispensing (clinicaltrials.gov) -  Jul 26, 2018   
    P4,  N=250, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  Mifepristone for the Prevention of Relapses of Alcohol Drinking (clinicaltrials.gov) -  Jul 10, 2018   
    P1/2,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. (Pubmed Central) -  Jun 28, 2018   
    However, the FDA-approved nonselective, steroidal GR antagonist, mifepristone, lacks GR specificity, reducing its therapeutic potential...Transcriptome analysis following AR blockade and GR activation revealed that these SGRMs block GR-mediated proliferative gene expression pathways. Furthermore, GR-regulated proliferation-associated genes AKAP12, FKBP5, SGK1, CEBPD, and ZBTB16 are inhibited by CORT108297 treatment in vivo Together, these data suggest that GR-selective non-steroidal SGRMs potently inhibit GR activity and PC growth despite AR pathway inhibition demonstrating the therapeutic potential of SGRMs in GR-expressing CRPC.
  • ||||||||||  NN1213 / Novo Nordisk, Mifeprex (mifepristone) / Danco Laboratories
    Enrollment closed:  Non-surgical Alternatives to Treatment of Failed Medical Abortion (clinicaltrials.gov) -  Jun 25, 2018   
    P4,  N=326, Active, not recruiting, 
    Furthermore, GR-regulated proliferation-associated genes AKAP12, FKBP5, SGK1, CEBPD, and ZBTB16 are inhibited by CORT108297 treatment in vivo Together, these data suggest that GR-selective non-steroidal SGRMs potently inhibit GR activity and PC growth despite AR pathway inhibition demonstrating the therapeutic potential of SGRMs in GR-expressing CRPC. Recruiting --> Active, not recruiting